Jubilant Radiopharmacies

Executive Summary

Jubilant Radiopharmacies is the second-largest radiopharmacy network in the United States, compounding and delivering over 3 million doses annually of SPECT, PET, and therapeutic radiopharmaceuticals to more than 1,800 healthcare providers. Founded in 1995 and headquartered in Portland, the company operates a nationwide network of compounding pharmacies, offering a comprehensive portfolio of diagnostic and therapeutic agents, along with ancillary products and logistics solutions. As a private entity, Jubilant benefits from the growing demand for radiopharmaceuticals driven by precision medicine and theranostics, positioning it as a key partner for hospitals, clinics, and imaging centers. The company's scale and established distribution infrastructure provide a competitive moat in a fragmented market, though financial details remain undisclosed.

Upcoming Catalysts (preview)

• Q4 2026Expansion of theranostic partnerships or new radiopharmaceutical launches70% success
• Q1 2027FDA approval of novel radiopharmaceutical tracers increasing demand for specialized compounding60% success
• Q2 2027Strategic acquisition or geographic expansion into new U.S. markets50% success